Report Summary
Italy is an intriguing case study of how value-based healthcare, which looks at health outcomes of treatment relative to cost, can evolve. The country offers an interesting dichotomy between a pioneering approach to financing innovative treatments on the one hand, and a more complex and arguably less sophisticated institutional structure and measures for assessing healthcare outcomes on the other.
The structure of Italy’s system for health technology assessment (HTA) reflects both its origins as a way of containing rising healthcare costs and the country’s strong economic differences between the north and the south. The uneven organisation of HTA structures at the national and the regional level contrasts with the country’s leadership role in the area of financing innovative therapies, in which consultative and assessment structures are more varied and better established than in many other European countries.
Further reading:

Value-based healthcare in the UK: A system of trial and error
This Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the UK healthcare system.

Value-based healthcare in Portugal: Necessity is the mother of invention
This paper examines how the recent economic crisis has shaped health technology assessment; the role of the hospital sector; and promising initiatives in integrated care, family health units and a new process for the re-evaluation of health technologies.

Value-based healthcare in France: A slow adoption of cost-effectiveness criteria
This new Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences, explores important questions about the French healthcare system. How is healthcare innovation assessed in France? To what extent is value for money influencing price neg

Value-based healthcare in Spain: Regional experimentation in a shared governance setting
Value-based healthcare in Spain is an Economist Intelligence Unit (EIU) report, commissioned by Gilead Sciences. It looks at health outcomes of treatment relative to cost and at the structure of Spanish healthcare delivery.

